Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Do you offer bladder-sparing approaches as an alternative to cystectomy for surgery-eligible patients with muscle-invasive bladder cancer?

3
1 Answers

Mednet Member
Mednet Member
Medical Oncology · University of Washington School of Medicine

We have a bladder cancer multispecialty clinic at SCCA/UWMC in which we also see patients with localized MIBC and we balance carefully risks vs benefits, rationale, data, details & logistics of options. Overall, cisplatin-based chemotherapy (for fit patients) ->radical cystectomy with PLND, OR maxim...

Is there a role for a salvage lymph node dissection in patients who present with a biochemical failure after prostatectomy?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Utah School of Medicine

It's an important question without randomized data to support an answer. Even this question will evolve as we bring on-board more advanced imaging such as Fluciclovine PET/CT, PSMA PET, etc. These scans are continuuing to introduce new challenges as we start to resolve the location of lesions and so...

Which chemotherapy regimen (if any) do you recommend for palliative concurrent chemoradiation for a symptomatic patient with metastatic cervical carcinoma and CKD stage 4 (GFR 15-29)?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

For patients who cant get cisplatin because of poor kidney function, we have used taxol at 45-50 mg/m2 weekly ( metabolized through liver) based on phase 2 data. In our experience it is tolerated well.

When do you use IMRT in breast radiotherapy?

4
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We seldom use it. Our limited dosimetric experience shows that even though coverage of regional nodes improves, the V10 and V20 of the lung and the mean heart dose also increase. Thus, the small benefit of improved coverage (EORTC and Canadian data showed small improvement in DFS) has to be weighed ...

Is acute pancreatitis a contraindication to radiotherapy for patients with pancreatic cancer?

2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan-Kettering Cancer Center

No, it is not a contraindication to the use of radiotherapy. Radiotherapy has been used in the very distant past to treat acute pancreatitis. If anything radiotherapy will help reduce the inflammation.

What IGRT strategy do you use when treating intact prostate?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Emory University School of Medicine

We typically do gold fiduicials at our institution for all intact prostate cases and for all fractionation schemes. Only patients we do not do gold fiducials on are those who decline or those who have poor performance status [or otherwise unable to tolerate the gold marker procedure] - in these case...

What is the most appropriate management for a patient with a primary brain sarcoma?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Thomas Jefferson University Hospital

This is a complicated questions, since brain sarcoma covers a wide spectrum. For patients with gliosarcoma or glioblastoma with sarcoma component, they should be treated as GBM. They are eligible for most trials for GBM. Off protocol, they should receive chemo-RT per Stupp regimen. For other sarcoma...

How to you manage radiation brachial plexopathy in head & neck patients?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Michigan

I am not aware of any effective therapy for brachial plexopathy. Bevacizumab has been reported to be beneficial in radiation-induced brain and retinal injury but I am not aware of its use in neuropathy. In any case, brachial plexopathy after RT of HN cancer is quite rare. I do not recall any BP case...

Is your decision to treat with hypofractionated radiation impacted by histology, ie lobular vs ductal cancers?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Our present approach is to treat all patients (ductal and lobular) and all phenotype with hypofractionation (where we treat breast without RNI) followed by boost. If we feel a patient would benefit from a higher dose we would increase the boost dose but still do hypofractionation for the breast

Do you time initiation of definitive radiation on PSA response to neoadjuvant ADT?

4
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

In the setting of definitive RT, I will generally wait 2-3 months before beginning radiation for 2 reasons. First, during that period of time the prostate may shrink by as much as a third of it's original size, which may adversely impact on the normal tissue dosimetry if this were to occur during th...